PMID- 37633162
OWN - NLM
STAT- MEDLINE
DCOM- 20230911
LR  - 20230911
IS  - 1873-264X (Electronic)
IS  - 0731-7085 (Linking)
VI  - 235
DP  - 2023 Oct 25
TI  - Comparative pharmacokinetic analysis of six major bioactive constituents using 
      UPLC-MS/MS in samples isolated from normal and diabetic nephropathy rats after 
      oral administration of Gushen Jiedu capsule.
PG  - 115638
LID - S0731-7085(23)00407-7 [pii]
LID - 10.1016/j.jpba.2023.115638 [doi]
AB  - Berberine, palmatine, physcion, rhein, calycosin-7-O-glucoside, and ferulic acid 
      are six major active consituents that are present in Gushen Jiedu capsule (GSJD) 
      extracts. The aim of this study was to determine the pharmacokinetics of the six 
      active consituents in vivo by a rapid, sensitive, and precise UPLC-MS/MS method, 
      which were compared between normal and diabetic nephropathy (DN) rats. Good 
      separation of the target analytes and internal standards (ketoprofen and 
      puerarin) was obtained on a Waters BEH C(18) UPLC column with a mobile phase of 
      0.1 % formic acid acetonitrile-0.1 % formic acid water. All the calibration 
      curves showed good linearity with a regression coefficient (r(2)) of >/= 0.9908. 
      The lower limits of quantification (LLOQ) for berberine, palmatine, physcion, 
      rhein, calycosin-7-O-glucoside, and ferulic acid were 20, 2.5, 20, 20, 2.5, and 
      2.5 ng/mL, respectively. The relative standard deviations (RSDs) of intra-day and 
      inter-day precision were all within 12.66 %, and the relative errors of intra-day 
      and inter-day accuracy ranged from - 15.00 to 14.93 %. Good extraction recovery 
      and matrix effects were obtained. The stability study confirmed the stability of 
      the six analytes (RSD < 15 %). Finally, the data showed that the pharmacokinetic 
      parameters (especially CLz/F, AUC and T(max)) of the six target analytes in DN 
      rats were significantly different from those in normal rats. PK studies under 
      pathological conditions could provide new thoughts to elucidate the underlying 
      mechanism of GSJD and promote the clinical development of GSJD to treat DN.
CI  - Copyright (c) 2023 Elsevier B.V. All rights reserved.
FAU - Zhang, Lei
AU  - Zhang L
AD  - Department of Pharmacy, Beijing Shijitan Hospital, Capital Medical University, 
      Beijing, China; Beijing Key Laboratory of Bio-characteristic Profiling for 
      Evaluation of Rational Drug Use, Beijing, China.
FAU - Yang, Chunjing
AU  - Yang C
AD  - Department of Pharmacy, Beijing Shijitan Hospital, Capital Medical University, 
      Beijing, China; Beijing Key Laboratory of Bio-characteristic Profiling for 
      Evaluation of Rational Drug Use, Beijing, China.
FAU - Zhao, Yidan
AU  - Zhao Y
AD  - Department of Pharmacy, Fuwai Central China Cardiovascular Hospital, Zhengzhou, 
      China.
FAU - Yang, Zhirui
AU  - Yang Z
AD  - Beijing Key Laboratory of Bio-characteristic Profiling for Evaluation of Rational 
      Drug Use, Beijing, China; Beijing Institute of Clinical Pharmacy, Beijing 
      Friendship Hospital, Capital Medical University, Beijing, China.
FAU - Meng, Xintong
AU  - Meng X
AD  - Beijing Key Laboratory of Bio-characteristic Profiling for Evaluation of Rational 
      Drug Use, Beijing, China.
FAU - Yan, Dan
AU  - Yan D
AD  - Beijing Institute of Clinical Pharmacy, Beijing Friendship Hospital, Capital 
      Medical University, Beijing, China; Department of Pharmacy, Beijing Friendship 
      Hospital, Capital Medical University, Beijing, China. Electronic address: 
      danyan@ccmu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20230811
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - AVM951ZWST (ferulic acid)
RN  - 0YIW783RG1 (formic acid)
RN  - H6PT94IV61 (physcione)
RN  - YM64C2P6UX (rhein)
RN  - 0I8Y3P32UF (Berberine)
RN  - 0 (Glucosides)
SB  - IM
MH  - Animals
MH  - Rats
MH  - *Berberine
MH  - Chromatography, High Pressure Liquid
MH  - Chromatography, Liquid
MH  - *Diabetic Nephropathies/drug therapy
MH  - Tandem Mass Spectrometry
MH  - Administration, Oral
MH  - Glucosides
MH  - *Diabetes Mellitus
OTO - NOTNLM
OT  - Diabetic nephropathy
OT  - Gushen Jiedu capsule
OT  - Pharmacokinetics
OT  - UPLC-MS/MS
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/08/27 05:43
MHDA- 2023/09/11 06:42
CRDT- 2023/08/26 18:08
PHST- 2023/04/21 00:00 [received]
PHST- 2023/07/07 00:00 [revised]
PHST- 2023/08/07 00:00 [accepted]
PHST- 2023/09/11 06:42 [medline]
PHST- 2023/08/27 05:43 [pubmed]
PHST- 2023/08/26 18:08 [entrez]
AID - S0731-7085(23)00407-7 [pii]
AID - 10.1016/j.jpba.2023.115638 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 2023 Oct 25;235:115638. doi: 10.1016/j.jpba.2023.115638. 
      Epub 2023 Aug 11.